Search results
Jul 28, 2024 · Moderna Inc.'s herpes simplex virus (HSV) vaccine candidate (mRNA-1608) is a Messenger RNA (mRNA) vaccine targeted against HSV-2 disease. On February 18, 2022, Moderna Inc. stated that it expects an HSV-2 vaccine could provide cross-protection against HSV-1.
Moderna is developing a vaccine using mRNA technology to treat the herpes simplex virus (HSV). There are two HSV virus types — HSV-1, the one I have, that affects the mouth, face and...
- Deidre Olsen
- 7 min
- Award-Nominated Writer Based in Berlin
5 days ago · Fact checked by. Robert Carlson, MD + Holly Lutmer PharmD. Follow. Herpes Vaccines 2024. Developing protective herpes simplex virus (HSV) vaccines has been an ongoing clinical trial challenge for decades.
Dec 7, 2021 · Although there are no currently available vaccines for herpes simplex 1 and 2, there are various candidates in both the pre-clinical and the clinical phases currently in development. Vaccines are being developed with two broad focuses: preventative and therapeutic, some with a dual use.
- Rohini Krishnan, Patrick M. Stuart
- Front Microbiol. 2021; 12: 798927.
- 10.3389/fmicb.2021.798927
- 2021
Herpes simplex virus (HSV) has coevolved with Homo sapiens for over 100,000 years, maintaining a tenacious presence by establishing lifelong, incurable infections in over half the human population. As of 2024, an effective prophylactic or therapeutic vaccine for HSV remains elusive. In this review, we independently screened PubMed, EMBASE, Medline, and Google Scholar for clinically relevant ...
Dec 21, 2022 · Dec 21 (Reuters) - BioNtech (22UAy.DE) has dosed the first patient with its BNT163 herpes vaccine candidate designed to prevent genital lesions as part of a first-in-human Phase 1 clinical...
Apr 24, 2022 · PPK vaccine is expected to help STOP the virus reactivation from latently infected DRG, virus shedding and virus replication in CGMC, thus curing or reducing recurrent genital herpes disease.
